Treatment with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has reportedly resulted in tumor control and hearing improvement in NF2 patients6, presumably because VEGF-A is essential for the growth of these tumors. Here, VEGFA is linked to neoplasm.